The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
A novel resource centre for TP53 mutations and mutants has been developed (http://p53.fr). TP53 gene dysfunction can be found in the majority of human cancer types. The potential use of TP53 mutation as a biomarker for clinical studies or exposome analysis has led to the publication of thousands of reports describing the TP53 gene status in >10,000 tumours. The UMD TP53 mutation database was created in 1990 and has been regularly updated. The 2012 release of the database has been carefully curated, and all suspicious reports have been eliminated. It is available either as a flat file that can be easily manipulated or as novel multi-platform analytical software that has been designed to analyse various aspects of TP53 mutations. Several tools to ascertain TP53 mutations are also available for download. We have developed TP53MULTLoad, a manually curated database providing comprehensive details on the properties of 2549 missense TP53 mutants. More than 100,000 entries have been arranged in 39 different activity fields, such as change of transactivation on various promoters, apoptosis or growth arrest. For several hot spot mutants, multiple gain of function activities are also included. The database can be easily browsed via a graphical user interface.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most oncogenic p53 mutations are missense mutations in the highly conserved DNA-binding domain (DBD) [5, 6] and have been classified as either DNA-contact mutations or structural mutations [7–9].”
From Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog (2022) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion
Dunnen, J. T. D., & Antonarakis, S. E. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<7::aid-humu4>3.0.co;2-n · Cited by 1,756
Predicting the Effects of Amino Acid Substitutions on Protein Function
Ng, P. C., & Henikoff, S. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.7.080505.115630 · Cited by 978
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“TP53 mutation databases have also been a framework for many studies on the structure–function relationship of the TP53 protein and the design of novel drugs that can target specific mutant TP53 (4).”
BackgroundKato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
Self-citationMutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Self-citationTP53 tumor suppressor gene: A model for investigating human mutagenesis
Fromentel, C. C. D., & Soussi, T. (1992) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870040102 · Cited by 574
Self-citationDistinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
p53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
Ikediobi, O. N., Davies, H., Bignell, G., Edkins, S., Stevens, C., O'Meara, S., Santarius, T., Avis, T., Barthorpe, S., Brackenbury, L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0433 · Cited by 440
Clinical Outcomes and Correlates of TP53 Mutations and Cancer
Robles, A. I., & Harris, C. C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001016 · Cited by 394
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Human Gene Mutation Database?A biomedical information and research resource
Krawczak, M., Ball, E. V., Fenton, I., Stenson, P. D., Abeysinghe, S., Thomas, N., & Cooper, D. N. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<45::aid-humu10>3.0.co;2-t · Cited by 273
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
Self-citationp53 gene mutation: software and database
Beroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 187
Locus-specific mutation databases: pitfalls and good practice based on the p53 experience
Soussi, T., Ishioka, C., Claustres, M., & Béroud, C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1783 · Cited by 161
Self-citationThe UMD-p53 database: New mutations and analysis tools
Béroud, C., & Soussi, T. (2003) · Human Mutation · doi:10.1002/humu.10187 · Cited by 155
Self-citationIn vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR
Quach, N., Goodman, M. F., & Shibata, D. K. (2004) · BMC Clinical Pathology · doi:10.1186/1472-6890-4-1 · Cited by 149
p53 gene mutation: software and database
Beroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 147
The UMD TP53 database and website: update and revisions
Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Béroud, C., & Soussi, T. (2006) · Human Mutation · doi:10.1002/humu.20269 · Cited by 140
Self-citationSoussi, T., Kato, S., Levy, P. P., & Ishioka, C. (2005) · Human Mutation · doi:10.1002/humu.20114 · Cited by 136
Self-citationBerglind, H., Pawitan, Y., Kato, S., Ishioka, C., & Soussi, T. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5712 · Cited by 102
Self-citationDatabase and software for the analysis of mutations in the human p53 gene.
Cariello, N. F., Cui, L., Béroud, C., & Soussi, T. (1994) · Europe PMC (PubMed Central) · Cited by 92
Self-citationTP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Soussi, T. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00005-0 · Cited by 86
Self-citationp53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma
de Cremoux, P., Vincent Salomon, A., Liva, S., Dendale, R., Bouchind'homme, B., Martin, E., Sastre-Garau, X., Magdelenat, H., Fourquet, A., & Soussi, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.641 · Cited by 82
Self-citationSoussi, T., Asselain, B., Hamroun, D., Kato, S., Ishioka, C., Claustres, M., & Béroud, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0413 · Cited by 81
Self-citationEdlund, K., Larsson, O., Ameur, A., Bunikis, I., Gyllensten, U., Leroy, B., Sundström, M., Micke, P., Botling, J., & Soussi, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200019109 · Cited by 79
Self-citationTranscriptional functionality of germ line p53 mutants influences cancer phenotype
Monti, P., Ciribilli, Y., Jordan, J., Menichini, P., Umbach, D. M., Resnick, M. A., Luzzatto, L., Inga, A., & Fronza, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2545 · Cited by 58
Self-citationDatabase and software for the analysis of mutations at the human hprt gene.
Cariello, N. F., Béroud, C., & Soussi, T. (1994) · Europe PMC (PubMed Central) · Cited by 45
Self-citationElegance, silence and nonsense in the mutations literature for solid tumors
Kern, S. E., & Winter, J. M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.4.2551 · Cited by 25
Soussi, T. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.07.003 · Cited by 21
Self-citationIntroduction: The Changing Directions of p53 Research
Levine, A. J. (2011) · Genes & Cancer · doi:10.1177/1947601911413463 · Cited by 18
p53 and APC gene mutations: software and databases
Béroud, C., & Soussi, T. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.1.138 · Cited by 18
Self-citation
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 446
Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82
Metadata
- Authors
- Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T.
- Affiliations
- Université Pierre-et-Marie-Curie (FR)
- Tohoku University (JP)
- Ospedale Policlinico San Martino (IT)
- University of Trento (IT)
- Karolinska Institutet (SE)
- Corresponding author
- Soussi, Thierry
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-17
- Volume
- 41
- Issue
- D1
- Pages
- D962-D969
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC3531172
- OpenAlex
- W2041908101
- Cited by
- 185
- References
- 39
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 6 · 2022: 19 · 2021: 14 · 2020: 18 · 2019: 15 · 2018: 18 · 2017: 18 · 2016: 15 · 2015: 9 · 2014: 15 · 2013: 3 · 2012: 1
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Funders
- Cancerfonden
- Vetenskapsrådet
- Associazione Italiana per la Ricerca sul Cancro (IG#5506)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- TP53, TP53 mutation, missense mutants, gain-of-function, transcriptional activation, apoptosis, tumour biomarkers, cancer genomics, database curation
- MeSH terms
- Humans, Mutation, Neoplasms, Genes, p53, Tumor Suppressor Protein p53, Internet, Databases, Nucleic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.